- Home
- PIM vs ANTX Comparison
PIM vs ANTX Comparison
Compare PIM & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIM | ANTX |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 158.8M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PIM | ANTX |
|---|---|---|
| Price | $3.19 | $4.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 44.0K | ★ 412.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $64.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.07 | $1.00 |
| 52 Week High | $3.50 | $6.91 |
Technical Indicators
Market Signals| Indicator | PIM | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 47.50 |
| Support Level | $3.14 | $3.82 |
| Resistance Level | $3.24 | $5.21 |
| Average True Range (ATR) | 0.03 | 0.39 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 70.00 | 29.58 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.